ATAI Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
ATAI Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech's novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.
旨在改變心理健康障礙治療的臨床階段生物製藥公司atai Life Sciences（納斯達克股票代碼：ATAI）（“atai” 或 “公司”）今天宣佈發佈了貝克利心理科技新型 5-meo-DMT 鼻內苯甲酸鹽配方 BPL-003 的第一階段結果 心理藥理學雜誌。
The double-blind, placebo-controlled, single ascending dose Phase 1 study explored the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003 in combination with psychological support in 44 psychedelic-naïve healthy volunteers. Participants across seven cohorts were given either a single dose of BPL-003 between 1 mg to 12 mg or a placebo.
這項雙盲、安慰劑對照、單次遞增劑量的第 1 期研究探討了 BPL-003 的安全性、耐受性、藥代動力學 (PK) 和藥效學 (PD)，以及對 44 名迷幻天真的健康志願者的心理支持。七個隊列的參與者要麼服用介於 1 mg 到 12 mg 之間的單劑量 BPL-003，要麼服用安慰劑。